Therapy monitoring with FDG PET in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy.

被引：0
|
作者：
Dimitrakopoulou-Strauss, A
Strauss, L
Rudi, J
机构：
[1] German Canc Res Ctr, D-6900 Heidelberg, Germany
[2] Theresienkrankenhaus, Mannheim, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2002年 / 43卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
79
引用
收藏
页码：22P / 23P
页数：2
相关论文
共 50 条
  • [1] Therapy monitoring with FDG-PET in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss, A
    Rudi, J
    Strauss, LG
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 113P - 113P
  • [2] Multivariate prospective pharmacogenetic analysis in patients with resectable metastatic colorectal cancer (mCRC) receiving FOLFOX chemotherapy.
    Etienne-Grimaldi, Marie-Christine
    Hebbar, Mohamed
    De Gramont, Aimery
    Chibaudel, Benoist
    Andre, Thierry
    Formento, Patricia
    Llorca, Laurence
    Hadengue, Alexandra
    Mineur, Laurent
    Khalil, Ahmed
    Dutel, Jean Luc
    Ychou, Marc
    Mabro, May
    Smith, Denis Michel
    Faroux, Roger
    Brusquant, David
    Truant, Stephanie
    Paye, Francois
    Auby, Dominique
    Milano, Gerard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy
    Dimitrakopoulou-Strauss, A
    Strauss, LG
    Burger, C
    Rühl, A
    Irngartinger, G
    Stremmel, W
    Rudi, J
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (09) : 1480 - 1487
  • [4] Prognosis of therapy response with FDG-PET in metastatic colorectal carcinomas after FOLFOX chemotherapy
    Dimitrakopoulou-Strauss, A
    Rudi, J
    Burger, C
    Strauss, LG
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 961 - 961
  • [5] Carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer receiving systemic chemotherapy.
    Sunga, AY
    Ailawadhi, S
    Yang, GY
    Rajput, A
    Smith, JL
    Fakih, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 274S - 274S
  • [6] Feasibility of dignity therapy in patients with stage IV colorectal cancer receiving chemotherapy.
    Vergo, Maxwell Thomas
    Nimeiri, Halla Sayed
    Mulcahy, Mary Frances
    Von Roenn, Jamie H.
    Benson, Al Bowen
    Emanuel, Linda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Sarkar, S.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 154S - 154S
  • [8] Survival of metastatic metaplastic breast cancer patients receiving chemotherapy.
    Kukunoor, Sparsha
    Lee, Anna
    Taiwo, Evelyn Oluwatoyin
    Schreiber, David
    Luhrs, Carol A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Amifostine pretreatment for patients with advanced colorectal cancer receiving folfox chemotherapy
    Arena, F.
    Kurzyna-Solinas, A.
    Stark, R. F.
    Ohri, A.
    Schiffer, C.
    Sulzbach, H.
    Jemison, D.
    Dolat, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345